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Previous studies suggest that the activation (autophosphorylation) of dsRNA-dependent protein kinase (PKR) can stimulate protein
degradation, and depress protein synthesis in skeletal muscle through phosphorylation of the translation initiation factor 2 (eIF2) on
the a-subunit. To understand whether these mediators are important in muscle wasting in cancer patients, levels of the phospho
forms of PKR and eIF2a have been determined in rectus abdominus muscle of weight losing patients with oesophago-gastric cancer,
in comparison with healthy controls. Levels of both phospho PKR and phospho eIF2a were significantly enhanced in muscle of cancer
patients with weight loss irrespective of the amount and there was a linear relationship between phosphorylation of PKR and
phosphorylation of eIF2a (correlation coefficient 0.76, P¼0.005). This suggests that phosphorylation of PKR led to phosphorylation
of eIF2a. Myosin levels decreased as the weight loss increased, and there was a linear relationship between myosin expression and
the extent of phosphorylation of eIF2a (correlation coefficient 0.77, P¼0.004). These results suggest that phosphorylation of PKR
may be an important initiator of muscle wasting in cancer patients.
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Patients with cancer, especially those of the gastrointestinal tract,
show a progressive wasting of skeletal muscle, which reduces both
their quality of life and survival time (DeWys et al, 1980). Skeletal
muscle atrophy is characterised by a decreased protein content,
fibre diameter, force production and fatigue resistance. Muscle
wasting is due to a combination of depressed protein synthesis
(Emery et al, 1984), and elevated endogenous protein breakdown,
with oxidation of the resultant amino acids (O’Keefe et al, 1990). In
cancer patients the mechanism for the depression in protein
synthesis is not known, while the increased protein degradation
has been attributed to an increased expression of the ubiquitin–
proteasome proteolytic pathway (Khal et al, 2005).
Several potential mediators of the cachectic process, including
proteolysis-inducing factor (PIF) and angiotensin II (Ang II),
inhibit protein synthesis in skeletal muscle (Lorite et al, 1997;
Russell et al, 2006a), and also stimulate degradation, through
increased activity and expression of the ubiquitin–proteasome
pathway (Lorite et al, 2001; Sanders et al, 2005). We have recently
shown (Eley and Tisdale, 2007) a link between the ability of PIF
and Ang II to inhibit protein synthesis and increase protein
degradation in murine myotubes through the dsRNA-dependent
protein kinase (PKR). dsRNA-dependent protein kinase is a
serine/threonine-specific protein kinase, which undergoes
autophosphorylation at multiple serine and threonine residues,
causing activation, in the presence of double-stranded (ds)RNA, in
response to viral attack (Jammi and Beal, 2001). Both PIF and Ang
II were shown to induce autophosphorylation of PKR. Activated
PKR can phosphorylate several protein substrates including the
a-subunit of the heterotrimeric translation initiation factor 2
(eIF2a) (deHaro et al, 1996). Phosphorylation of eIF2a inhibits
continued initiation of protein synthesis by the eIF2 complex,
which initiates Met tRNA binding to the 40S ribosomal subunit.
During this process GTP associated with eIF2 is hydrolysed to
GDP, and recycling of eIF2-GDP to eIF2-GTP requires a guanine
nucleotide exchange factor eIF2B (Price and Proud, 1994).
Phosphorylation of eIF2 on the a-subunit causes it to act as an
inhibitor of eIF2B and the reduction in eIF2-GTP levels reduces
general translation (Rowlands et al, 1998) (Figure 1). Thus
activation of PKR by PIF and Ang II was responsible for the
depression in protein synthesis, since transfection of myotubes
with a mutant PKR incapable of autophosphorylation and
induction of phosphorylation of eIF2a, completely attenuated the
depression in protein synthesis by both agents (Eley and Tisdale,
2007). Mutation of PKR also completely attenuated the induction
of protein degradation and upregulation of the ubiquitin–
proteasome pathway. Induction of the ubiquitin–proteasome
pathway by both PIF (Wyke and Tisdale, 2005) and Ang II
(Russell et al, 2006b) requires activation of the transcription factor
nuclear factor-kB (NF-kB). dsRNA-dependent protein kinase has
been shown to activate the upstream kinase IkB kinase (IKK)
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sleading to degradation of the inhibitor protein IkB, leading to
release of NF-kB, which migrates to the nucleus and induces
transcriptional activation of specific genes (Zamanian-Daryoush
et al, 2000). Myotubes containing mutant PKR showed no
activation of NF-kB in response to either PIF or Ang II, and no
induction of the ubiquitin–proteasome pathway (Eley and Tisdale,
2007), suggesting that NF-kB activity is required for the induction
of ubiquitin–proteasome pathway by PKR (Figure 1). Thus
activation of PKR leads potentially to both a depression of protein
synthesis and an increase in protein degradation in skeletal
muscle. These studies in vitro were also reflected by changes in
vivo in gastrocnemius muscle of mice bearing a cachexia-inducing
tumour, where levels of phosphorylated PKR and eIF2a were found
to increase with increasing weight loss by as much as 18-fold for
PKR at 25% weight loss (Eley and Tisdale, 2007).
To determine whether changes similar to those induced by PIF
and Ang II also occur in human cancer cachexia, the present study
examines the levels of phosphorylation of PKR and eIF2a in
skeletal muscle of weight-losing patients with upper gastrointest-
inal cancer, in comparison with healthy, weight-stable subjects
undergoing minor elective surgery.
PATIENTS AND METHODS
Cancer patients and controls
Patients provided written, informed consent, and the study was
approved by the Lothian Research Ethics Committee. Twenty-nine
patients with newly-diagnosed oesophago-gastric adenocarcinoma
who were undergoing elective resection of their primary cancer
were recruited for the study. Oesophago-gastric cancer patients
have a high incidence of weight loss (DeWys et al, 1980) and were
mRNA 43S
43S
40S
Met-tRNA
elF2-GDP
elF2
elF2
PKR PKR
PIF
IKK IKK
Increased protein
degradation
Degradation Proteasome
protein
Proteasome
mRNA
Nucleus
NF-B/B NF-B+IB
P
elF2-GTP
GTP
elF2B
(Inhibition of
protein synthesis)
mRNA
P
P
P
Figure 1 Summary of pathways leading to a depression in protein synthesis and an increase in protein degradation in skeletal muscle through activation of
PKR.
Table 1 Demographics of the weight-losing cancer patients and weight-
stable, healthy, noncancer controls
Healthy controls Cancer patients
Number (n)9 1 5
Sex
Male 9 13
Female 0 2
Age (years) 56 (41–86) 66 (49–83)
Tumour site
Oesophageal N/A 6
Gastric 8
Histology
ACC N/A 14
SCC 1
Stage
I3
II N/A 3
III 6
IV 3
BMI (kg/m
2) 28.5 (19.6–35.2) 26.1 (20.1–34.4)
MAC (cm) 32.6 (25.5–35.2) 28.9 (23.0–40.0)
TSF (mm) 15.5 (5.0–29.4) 14.4 (7.8–37.4)
MAMC (cm) 25.8 (23.8–30.5) 25.3 (18.3–30.0)
KPS 100 (100–100) 90
a (60–100)
Weight loss (%) 0 7.8
b (0.0–27.5)
Abbreviations: BMI¼body mass index; KPS¼Karnofsky performance score;
MAC¼mid-arm circumference; MAMC¼mid-arm muscle circumference; TSF¼triceps
skinfold thickness. Data are presented as medians with ranges in parentheses.
Differences are shown from healthy controls as
aPo0.05 and
bPo0.001.
Increased phospho PKR and eIF2a in muscle
HL Eley et al
444
British Journal of Cancer (2008) 98(2), 443–449 & 2008 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
stherefore chosen as a representative group of patients who develop
cancer cachexia. Muscle biopsies were also collected from 10
healthy, weight-stable volunteers who were undergoing elective
hernia surgery and who served as controls.
Muscle biopsy
A sample of rectus abdominis muscle was obtained from the edge
of the patients abdominal wound within 10min of induction of
general anaesthesia. The sample was obtained without the use of
diathermy and was frozen immediately in liquid nitrogen using
liquid nitrogen-resistant tubes (Corning BV, Netherlands). Sam-
ples were frozen at  701C until analysis.
Nutritional assessment
At the preoperative assessment, preillness stable weight was
self-reported by the patient. Height was measured using a wall-
mounted stadiometer with the patient standing erect without
shoes. Patients were weighed on spring balance scales without
shoes and wearing light clothing, and body mass index was
calculated. Mid arm circumference (MAC) was measured at the
midpoint between the acromion and olecranon processes. Triceps
skinfold thickness (TSF) was measured with Harpenden skin
callipers (Holtain, Crymych, UK). Mid arm muscle circumference
(MAMC) was calculated according to the formula: MAC-
[p TSF]¼MAMC. Karnofsky performance score was documen-
ted by the recruiting physician.
Molecular biology materials
Rabbit polyclonal antibody to phospho PKR (pThr 446), was
purchased from Insight Biotechnology, (Wembley, Middlesex, UK)
and to total PKR (C terminus) from New England Biolabs, (Herts,
UK). Rabbit polyclonal antisera to total eIF2a was purchased from
Santa Cruz Biotechnology (CA, USA) and rabbit polyclonal
antisera to phospho eIF2a was purchased from Abcam
(Cambridge, UK). Mouse monoclonal antibody to myosin heavy
chain was from Novocastra (Newcastle, UK). Rabbit polyclonal
antiserum to actin was from Sigma Aldridge (Dorset, UK).
Peroxidase-conjugated goat anti-rabbit antibody and peroxidase-
conjugated rabbit anti-mouse antibody were purchased from Dako
Ltd (Cambridge, UK). PhosphoSafet extraction reagent was
obtained from Merck Biosciences, (Nottingham, UK). Hybond A
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Figure 2 Western blots of phospho PKR (A) and eIF2a (B) in comparison with total PKR and eIF2a in rectus abdominus muscle of healthy controls (HC)
and cancer patients as a function of weight loss. Actin was used as a loading control. Each lane represents muscle from an individual patient. The specificity of
the antibodies is given in Patients and Methods section. A densitometric analysis of the ratio of phospho to total forms is given underneath and represents
the average of three separate blots. Differences from healthy controls are shown as a, Po0.05 or b, Po0.01. c, Po0.001.
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snitrocellulose membranes and enhanced chemiluminescence
(ECL) development kits were from Amersham Biosciences Ltd
(Bucks, UK).
Western blot analysis
Samples (approximately 10mg) of muscle were homogenised in
500ml of PhosphoSafet Extraction Reagent and centrifuged at
15000g for 15min. Samples of cytosolic protein (10mg) were
resolved on 10% sodium dodecylsulphate polyacrylamide gels (6%
for eIF2a) and transferred to 0.45mm nitrocellulose membranes,
which had been blocked with 5% marvel in Tris-buffered saline,
pH 7.5, at 41C for 1–2h. Membranes were then washed for 15min
in 0.5% Tween-buffered saline or TBS Tween prior to adding the
primary antibodies. The primary antibodies were used at a dilution
of 1:1000 except for actin (1:250) and anti-myosin (1:100).
Incubation was at 41C overnight, except for total eIF2a (1–2h at
room temperature). The primary antibodies were washed off the
membranes for 15min (changing the wash every 5min), except for
actin, which was washed for 45min (changing the wash every
15min). TBS Tween (0.1%) was used for washing phospho
antibodies and total antibodies. The secondary antibodies were
used at a dilution of 1:1000, and were washed off after 45min.
Development was by ECL and films were developed for 3–6min.
Blots were scanned by a densitometer to quantify differences.
Statistical analysis
Western blot densitometry results are presented as means±s.e.m.
for at least three replicate experiments. Differences in means
between groups were determined by one-way analysis of variance,
followed by Tukey–Kramer multiple comparison test. Significance
level was set at Po0.05.
RESULTS
The characteristics of the patients in this study is shown in Table 1.
Muscle biopsies from healthy subjects undergoing elective surgery
for hernia served as weight stable controls. The weight losing
subjects had oesophago-gastric cancer and had a weight loss at the
time of operation between 2.4 and 27.5%. As a comparison some
patients with oesophago-gastric cancer without weight loss were
also included.
Western blots for the phospho and dephospho forms of PKR
and eIF2a in rectus abdominus muscle as a function of weight loss
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Figure 3 Western blots of phospho PKR (A) and eIF2a (B) in comparison with total PKR and eIF2a in rectus abdominus muscle of healthy controls (HC)
and cancer patients as a function of weight loss. Actin was used as a loading control. Each lane represents muscle from an individual patient. A densitometric
analysis of the ratio of phospho to total forms is given underneath and represents the average of three separate blots. Differences from healthy controls are
shown as a, Po0.05, b, Po0.01 or c, Po0.001.
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sis shown in Figures 2 and 3, which display values for different
patients. While there was no major change in total PKR or eIF2a
with weight loss, there was a significant increase in the
phosphorylated forms in all patients with weight loss, which,
however, did not show a tendency for increased expression with
increasing weight loss. Cancer patients with no weight loss, or
weight gain (Figure 2) showed the same low expression of
phosphorylated PKR and eIF2a, as nonweight-losing normal
subjects. There was a linear correlation between expression of
phosphorylated PKR and phosphorylated eIF2a (correlation
coefficient 0.76, P¼0.005), consistent with increased PKR activity
being responsible for the increased phosphorylation of eIF2 on the
a-subunit (Figure 4). Myosin levels decreased as the weight loss
increased (Figure 5A), and there was an inverse relationship
between the expression of myosin in rectus abdominus muscle and
the extent of phosphorylation of eIF2a (correlation coefficient 0.77,
P¼0.004) (Figure 5B). As previously reported (Acharyya et al,
2004) in skeletal muscle of mice bearing a cachexia-inducing
tumour (colon 26) myosin levels decreased, while actin levels
remained constant. This has been attributed to specific targeting of
myosin by the ubiquitin–proteasome pathway.
DISCUSSION
This is the first report to show an increased expression of
phosphorylated PKR and eIF2a in the skeletal muscle of weight-
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and phospho eIF2a to total PKR and eIF2a in skeletal muscle samples from
patients shown in either Figure 2A (A) or Figure 3B (B). The correlation
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Figure 5 (A) Western blot of myosin expression in comparison with actin as a loading control in rectus abdominis muscle of the patients shown in
Figure 3 as a function of weight loss. Each lane represents muscle from an individual patient. The densitometric analysis represents the average of three
separate blots. Differences from healthy controls are shown as a, Po0.05. (B) Ratio of phosphorylated to total PKR vs the myosin levels of the samples
shown in A. The correlation coefficient is 0.77, Po0.0004.
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slosing cancer patients compared with healthy weight-stable
controls. As found in the gastrocnemius muscle of weight-losing
mice bearing the MAC16 tumour (Eley and Tisdale, 2007),
expression of both phospho PKR and eIF2a increased in patients
with weight loss, although there was no trend to increased
expression with increasing weight loss. This suggests that the same
signalling mechanism is operative in the skeletal muscle of
cachectic cancer patients as that in mice with experimental cancer
cachexia. Similar findings have been observed in murine myotubes
in the presence of PIF or Ang II, and are thought to be responsible
for the depression in protein synthesis and increase in degradation
(Eley and Tisdale, 2007). dsRNA-dependent protein kinase is
normally activated in response to viral attack, and the depression
of protein synthesis resulting from phosphorylation of eIF2a
constitutes one of the major ways in which viral replication is
impaired (Clemens, 1997). However, PKR can also exert effects in
uninfected cells and can be a potent growth inhibitory protein
when activated (Chong et al, 1992). dsRNA-dependent protein
kinase is also linked to the induction of pro-apoptotic genes by
dsRNA, and may trigger cell death in response to viral infection
and possible tumorigenesis (Balachandran et al, 1998). Activation
of PKR by PIF may be responsible for its ability to induce
apoptosis in murine myotubes (Smith and Tisdale, 2003).
Increased apoptosis has also been observed in the skeletal muscle
of rats bearing the cachexia-inducing Yoshida AH-130 ascites
hepatoma (van Royen et al, 2000) and in the early stage of weight
loss in rabbits bearing the VX2 carcinoma (Yoshida et al, 2001).
In addition, muscle biopsies from weight losing patients with
upper gastro-intestinal cancer showed a threefold increase in DNA
fragmentation compared with control subjects, together with an
increased PARP cleavage and decrease in MyoD protein content
(Busquets et al, 2007). Thus activation of PKR might be
responsible for the increased apoptosis in the skeletal muscle of
weight-losing cancer patients contributing to muscle atrophy.
The increased phosphorylation of eIF2a is likely to contribute to
the depression of protein synthesis in the skeletal muscle of cancer
patients, through the inhibition of eIF2B and subsequent transla-
tional repression (Rowlands et al, 1998), as was previously
observed in murine myotubes treated with PIF and Ang II (Eley
and Tisdale, 2007). Phosphorylation of eIF2a has also been shown
to be responsible for the inhibition of protein synthesis in rat liver
by vasopressin (Kimball and Jefferson, 1990), and rat skeletal
muscle by interleukin-1 (Cooney et al, 1999). Phosphorylation of
PKR would also be expected to lead to an increased breakdown of
myofibrillar proteins in skeletal muscle by induction of the
ubiquitin–proteasome pathway (Wyke and Tisdale, 2005; Russell
et al, 2006b) through activation of NF-kB (Zamanian-Daryoush
et al, 2000) analogous to the effect of PIF and Ang II (Eley and
Tisdale, 2007).
In the current study, there was a linear relationship between
activation (autophosphorylation) of PKR and phosphorylation
of eIF2a, suggesting that PKR is responsible for this effect rather
than general control of gene expression, nondepressing 2, which is
expected to be activated (Anthony et al, 2004) by the reduction in
plasma levels of amino acids in cachectic subjects (Norton et al,
1985). Moreover, in myotubes expressing mutant PKR there was
no increase in phosphorylation of eIF2a in response to catabolic
stimuli (Eley and Tisdale, 2007) suggesting that PKR is the major
eIF2a kinase under such conditions.
In mice bearing the MAC16 tumour, which show a similar
elevation of phospho PKR in skeletal muscle with weight loss (Eley
and Tisdale, 2007), treatment with a PKR inhibitor, at a
concentration which reduced levels of phospho PKR down to that
found in non tumour-bearing animals, effectively attenuated the
depression of body weight, through an increase in lean body mass
(Eley et al, 2007). This was achieved through attenuation in both
the depression in protein synthesis and the increase in protein
degradation, as observed in murine myotubes exposed to either
PIF or Ang II (Eley and Tisdale, 2007). This suggests that muscle
atrophy in cachectic cancer patients may also be responsive to
inhibitors of PKR.
In addition to attenuation of cachexia, treatment of mice bearing
the MAC16 tumour with a PKR inhibitor also inhibited tumour
growth (Eley et al, 2007). In vitro studies (unpublished) also
showed sensitisation of MAC16 cells to the growth inhibitory
effects of gemcitabine and 5-fluoroacil. The MAC16 tumour also
shows elevated autophosphorylation of PKR and phosphorylation
of eIF2a, which has been linked to constitutive activation of NF-kB
and chemoresistance (unpublished). Other studies have also
shown an increased autophosphorylation of PKR and phosphory-
lation of eIF2a in human breast carcinoma cell lines, compared
with nontransformed epithelial cells (Kim et al, 2000), and in
human melanoma cells compared with nontransformed melano-
cytes in culture (Kim et al, 2002). In addition analysis of colon
cancer specimens showed that transformation from normal
mucosa to adenomas and carcinomas coincided with an increase
in PKR expression (Kim et al, 2002). These results suggest a
positive role of PKR in cancer progression and growth control of
tumour cells. This suggests that inhibitors of PKR may not only be
effective in attenuating muscle wasting in cancer patients, but may
also induce antitumour effects or synergise with existing
chemotherapy.
The changes that are seen may be part of a common signalling
mechanism found in conditions where muscle atrophy occurs.
Thus PIF has been found in the urine of weight-losing cancer
patients, and when purified and administered to mice causes
muscle atrophy (Cariuk et al, 1997). Ang II has also been linked
with muscle wasting in congestive heart failure (Onder et al, 2002),
and tumour necrosis factor-a, which may be linked to muscle
wasting in sepsis, AIDS and parasitic infections, as well as cancer,
has also been shown to activate PKR (Jeffrey et al, 2002). Burn
injury, which also causes muscle atrophy, is also associated with an
increased phosphorylation of eIF2a as a result of a 274% increase
in phosphorylation of PKR (Kaneki et al, 2004). This suggests that
inhibitors of PKR autophosphorylation may have a general role in
the treatment of muscle atrophy.
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